Vehicle-treated and RO-3306 monotherapy-treated xenograft tumors showed low ID2 protein levels but upregulation of CDK1 and TFCP2L1 (Fig. 6g), along with BC stemness feature markers, including CD44 and KRT14 (Supplementary Fig. 11). This evidence concerns the gene ID2 and breast cancer.